< BACK iPROLEPSIS Showcased at MEDICA 2025 Nov 25, 2025 Project presented by PLUX at an international medical technology trade fair MEDICA 2025 was held in Düsseldorf, Germany, from 17–20 November 2025 and is one of the largest international trade fairs for medical technology and healthcare. iPROLEPSIS was showcased by project partner PLUX at MEDICA 2025, within a shared exhibition space alongside other Portuguese entities. The event offered an opportunity to present the project to industry and healthcare stakeholders and to engage with a broad international audience. MEDICA 2025 2.HEIC MEDICA 2025 1.HEIC MEDICA 2025 2.HEIC 1/2 PREVIOUS NEXT

< BACK Dynamic Difficulty Adjustment in Psoriatic Arthritis Serious Games Using Learning-Driven Policies Sep 1, 2026 New iPROLEPSIS publication presents machine learning approach to personalise game difficulty based on patient condition A new iPROLEPSIS publication presents a system that automatically adjusts game difficulty to match each patient's changing condition during therapeutic gameplay. The study proposes a Dynamic Difficulty Adjustment (DDA) system using machine learning – specifically Reinforcement Learning and Multi-Armed Bandits –to personalise how two serious games challenge players: Mr. Blue Sky, targeting wrist mobility, and The Kite, focusing on breathing and relaxation. Data were collected from 32 participants playing these games, tracking gameplay performance, physiological signals (heart rate and stress), and self-reported relaxation levels. Machine learning algorithms learned which difficulty progression works best based on how patient condition changes during play. Results showed that the best-performing strategies began gameplay at medium difficulty, then adjusted downward. In a feasibility pilot with six psoriatic arthritis patients, this automatic adjustment produced coherent therapeutic progressions while accounting for the fluctuating nature of patient symptoms. The system demonstrates how machine learning can support personalised rehabilitation, continuously adapting game challenges to patient needs rather than using fixed difficulty levels. Read the full publication: https://ieeexplore.ieee.org/document/11663158 iPROLEPSIS_Dynamic Difficulty adjustment in PsA publication.png iPROLEPSIS_Dynamic Difficulty adjustment in PsA publication.png 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS Clinical Studies' Planning Feb 13, 2023 iPROLEPSIS team starts the planning of the four clinical studies that will be conducted in the project. iPROLEPSIS team starts the planning of the four clinical studies that will be conducted in the project. iPROLEPSIS plans to carry out: 1) a study to design novel digital biomarkers for PsA; 2) a study to investigate new opto-acoustics biomarkers and the role of mast cells in PsA; 3) a study to validate the potential of the novel digital biomarkers to screen for PsA in persons with psoriasis; and 4) a study to evaluate the effectiveness of the envisioned iPROLEPSIS digital care ecosystem in reducing flares of persons with PsA. Office Scene .jpg Office Scene .jpg 1/1 PREVIOUS NEXT

< BACK Patient Voices in Research: Elaine’s Das Cheppo Journey with iPROLEPSIS Mar 4, 2025 A Patient’s Perspective: Elaine’s Journey with iPROLEPSIS Elaine Das Cheppo has been living with psoriatic arthritis for 25 years . Like many others, her diagnosis was delayed, making treatment more challenging in the early years. When her rheumatologist asked if she would like to take part in the iPROLEPSIS project , she did not hesitate. "I struggled in the beginning to understand why I was experiencing so much joint pain. By participating in this study, I hope to help future generations get a diagnosis faster than I did." The Role of Patient Partners in iPROLEPSIS Elaine is a patient partner in iPROLEPSIS, working alongside researchers to improve psoriatic arthritis care. She finds the co-creation sessions particularly insightful, offering her a behind-the-scenes look at how digital health solutions are developed. "It’s interesting to see how new technology is being used to improve diagnosis and treatment. These innovations could help people avoid unnecessary doctor visits and manage their condition more effectively." A Renewed Sense of Purpose For Elaine, being part of iPROLEPSIS is not just about contributing to research—it’s also about personal fulfillment . "For someone who has been retired for quite some time, it’s rewarding to have a new goal and interest in life. Being part of this project gives me a way to make a difference." Watch Elaine’s full story here: https://www.youtube.com/watch?v=BB0udK7B57w 1/1 PREVIOUS NEXT

Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search How is psoriatic arthritis diagnosed? See related Handbook section PREVIOUS NEXT

Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search How will psoriatic arthritis affect me? Relationships and Family Planning See related Handbook section PREVIOUS NEXT

< BACK iPROLEPSIS presented at the European OHDSI Symposium 2026 Apr 23, 2026 A poster presented in Rotterdam highlighted cross-country harmonization of psoriatic arthritis cohorts into the OMOP Common Data Model At the European OHDSI Symposium 2026 in Rotterdam, project partner AINIGMA presented a poster entitled Cross-Country Harmonization of Psoriatic Arthritis Cohorts: A Real-World Data Study in the context of the iPROLEPSIS project. Psoriatic arthritis affects 1–2% of the population and shows substantial heterogeneity in symptoms, progression, and treatment response. Real-world evidence is essential to understand long-term outcomes, sex differences, and disease trajectories that are difficult to capture in clinical trials. To identify key inflammation drivers, the team harmonised two national psoriatic arthritis cohorts – the Portuguese Reuma.pt registry and the Dutch DEPAR cohort – into the OMOP Common Data Model (OMOP CDM). This enabled standardised cross-country and sex-stratified analyses. The poster also presented data quality results for this harmonisation work, showing a 95% overall pass rate, including 99% for plausibility, 88% for conformance, and 90% for completeness. As highlighted in the conclusion of the poster, this work shows the value of harmonising data from different national psoriatic arthritis registries into the OMOP CDM to make standardised real-world analyses across European healthcare systems possible. It also opens up new possibilities for advanced analytics, such as federated studies and AI-driven prediction models, beyond this proof-of-concept analysis, advancing iPROLEPSIS’s goal of personalised, data-driven care. Poster_Final_Cross-Country Harmonization of Psoriatic Arthritis Cohorts A real-world data .pdf Download PDF • 1.66MB Media.jpg Media (1).jpg Media (2).jpg Media.jpg 1/3 PREVIOUS NEXT

< BACK Calling for Influencers: Join iPROLEPSIS as an Ambassador for Psoriatic Arthritis Feb 27, 2024 Join the iPROLEPSIS Initiative: Become an Ambassador for the iPROLEPSIS Project Join the iPROLEPSIS initiative! Calling all influencers, psoriatic arthritis warriors and health advocates to become iPROLEPSIS Ambassadors ! Our mission is to shed light upon the health-to-PsA transition through groundbreaking AI-driven analysis and cutting-edge technology. We are creating a digital health ecosystem for personalised psoriatic arthritis risk prediction and management. Are you passionate about health advocacy and psoriatic arthritis awareness? Become an iPROLEPSIS Ambassador and be a part of the change! Here is how you can make a difference as an iPROLEPSIS Ambassador: Promote the iPROLEPSIS mission Share iPROLEPSIS updates and developments Share personal stories and insights Ready to be a part of the change? Contact us at info@iprolepsis.eu , and we will provide you with more details. * Please note that this is voluntary, and no monetary compensation is offered. AI-PROGNOSIS events (8).png AI-PROGNOSIS events (8).png 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS at IEEE HealthCom 2025: AI-Enabled Digital Health for Psoriatic Arthritis Nov 3, 2025 Project researchers presented new studies, co-chaired a workshop, and joined a panel on digital innovation in healthcare in Abu Dhabi The iPROLEPSIS team participated in the IEEE HealthCom 2025 Conference , held 21–23 October 2025 and hosted by Khalifa University in Abu Dhabi, United Arab Emirates . The event gathered international experts in digital health , artificial intelligence , and biomedical technologies to discuss how AI can improve the understanding and management of non-communicable diseases . Modeling joint swelling through smartphone photographs Giorgos Apostolidis from the Signal Processing & Biomedical Technology Unit – AUTH presented the paper “Modeling Interphalangeal Joints for Swelling Assessment in Psoriatic Arthritis via Smartphone Photographs”. By analyzing smartphone photos of hands, the study showcased that a digital estimation of joint thickness, namely effective width , with the aid of a logistic regression model , can serve as an effective tool for detecting interphalangeal joint swelling in people with PsA .This approach was validated on a real-world dataset collected within the PDPID study . Giorgos Apostolidis (Signal Processing & Biomedical Technology Unit – AUTH) Designing exergames for Psoriatic Arthritis care Prof. Leontios Hadjileontiadis (AUTH) presented the paper “Designing Exergames for Psoriatic Arthritis: The Spy and Zen Forest Paradigms”. The Spy and Zen Forest exergames were co-designed to complement PsA care by making therapeutic exercises more engaging and accessible at home. Using real-time body tracking on mobile devices , these games promote dynamic movement to enhance mobility and strength, and calm stretching for flexibility and relaxation. Prof. Leontios Hadjileontiadis (Signal Processing & Biomedical Technology Unit-AUTH) Panel discussion: Digital Bridges for Better Health Project Coordinator Prof. Leontios Hadjileontiadis , Scientific & Technical Manager Vasileios Charisis , and Stelios Hadjidimitriou from the Signal Processing & Biomedical Technology Unit – AUTH , together with Dr. Kosmas Dimitropoulos from the Centre for Research & Technology Hellas (CERTH) and Prof. Mohamed Seghier from Khalifa University , participated in the panel discussion “Digital Bridges for Better Health: AI Innovation from Europe to the Middle East and North Africa (MENA),” moderated by Giorgos Apostolidis. The panel provided insights into: The technical challenges in integrating AI with existing healthcare IT systems, How key stakeholders can collaborate to ensure AI digital health tools are user-friendly and clinically relevant, The role of patient engagement and digital literacy in the effectiveness of AI tools in chronic disease management How socio-cultural differences between Europe and MENA can influence the design and adoption of AI digital health solutions What are the key regulatory challenges in Europe and MENA regarding the use of AI in healthcare and what joint efforts can be undertaken to harmonize standards in these regions During the session, the iPROLEPSIS project and its AI-enabled digital health tools for assisting Psoriatic Arthritis management and care were highlighted as a case study of AI solutions with potential to improve outcomes for people with non-communicable diseases . Panel discussion "Digital Bridges for better health: AI Innovation from Europe to the Middle East and North Africa (MENA)" Workshop chairing Scientific & Technical Manager Vasileios Charisis from the Signal Processing & Biomedical Technology Unit-AUTH co-chaired the workshop "AI-enabled Digital Health Tools for Non-Communicable Diseases: From Concepts to Impact" . The workshop was co-organised with the AI-PROGNOSIS Horizon Europe project and included research works in the fields of psoriatic arthritis, Parkinson's disease, multiple sclerosis and post-stroke rehabilitation. Two of the presented papers stem from research carried out within iPROLEPSIS: Apostolidis et al., Modeling Interphalangeal Joints for Swelling Assessment in Psoriatic Arthritis via Smartphone Photographs Ramalho et al., Designing exergames for psoriatic arthritis: The Spy and Zen Forest paradigms Workshop “AI-enabled Digital Health Tools for Non-Communicable Diseases: From Concepts to Impact” The iPROLEPSIS and AI-PROGNOSIS teams from AUTH participated jointly at IEEE HealthCom 2025 , highlighting their shared commitment to advancing AI-enabled digital health solutions that enhance the understanding, early detection, and management of chronic diseases . iPROLEPSIS and AI-PROGNOSIS team members PXL_20251021_131742947.MP.jpg 2.jpg IMG_2954.jpg PXL_20251021_131742947.MP.jpg 1/11 PREVIOUS NEXT

< BACK iPROLEPSIS 5th Plenary Meeting in Athens Dec 5, 2024 Advancing the Development of Digital Solutions for Psoriatic Arthritis Care The iPROLEPSIS consortium gathered in Athens, Greece, on 2-3 December 2024, for the 5th Plenary Meeting. Hosted by Netcompany-Intrasoft and Wellics, this two-day event brought together consortium partners, the External Advisory Board (EAB), and the Project Officer (PO) to discuss key updates and map out the next steps in developing a personalised digital care ecosystem for people with Psoriatic Arthritis (PsA). The meeting focused on project updates, key achievements, and future plans for the Psoriatic Arthritis digital care ecosystem. Day 1 covered progress in the project, co-creation activities, and updates from various work packages. The team also demonstrated the iPROLEPSIS tools, including the miPROLEPSIS apps, HCP’s dashboard, and the Lifestyle Recommendation System. On Day 2, workshops were held on study designs, ecosystem development, and predictive models. Discussions also focused on data governance and dissemination strategies. 1/8 PREVIOUS NEXT

< BACK Transforming Psoriatic Disease Care Through Innovation and Real-World Data: GRAPPA 2025 Soapbox Highlights May 18, 2026 The article highlights how iPROLEPSIS uses digital tools, smartphone-based data and explainable AI to support personalised psoriatic arthritis monitoring The iPROLEPSIS project has been featured in a newly published article in The Journal of Rheumatology , based on highlights from the GRAPPA 2025 Annual Meeting , held in Bogotá, Colombia. During the meeting, Dr. Vasileios Charisis presented the iPROLEPSIS approach to psoriatic arthritis monitoring. The project applies digital phenotyping and explainable artificial intelligence to analyse smartphone-based data, including typing dynamics and hand motion tracking. The article describes how these digital tools may help detect functional impairments related to psoriatic arthritis. Pilot data showed promising accuracy, supporting the potential of digital biomarkers for more personalised disease monitoring and management. Read the full paper: https://www.jrheum.org/content/early/2026/05/10/jrheum.2026-0371 jrheum.2026-0371.full .pdf Download PDF • 724KB 1/0 PREVIOUS NEXT

< BACK Modeling Interphalangeal Joints for Swelling Assessment in Psoriatic Arthritis via Smartphone Photographs Feb 5, 2026 New iPROLEPSIS publication presents a smartphone-based approach for remote joint swelling assessment in psoriatic arthritis A new publication from the iPROLEPSIS project has been published in the proceedings of the 2025 IEEE International Conference on E-health Networking, Application & Services (HealthCom) . The study investigates the use of smartphone photographs to support the remote assessment of swollen joints in patients with inflammatory arthritis, focusing on psoriatic arthritis. The proposed method classifies each interphalangeal joint in hand photographs as swollen or not swollen, supporting scalable and patient-friendly monitoring approaches. Read the full publication: https://zenodo.org/records/18481583 iPROLEPSIS_Apostolidis G._HealthCom.png iPROLEPSIS_Apostolidis G._HealthCom.png 1/1 PREVIOUS NEXT